HIV and hepatitis B co-infection in Africa. Lancet Infectious Diseases, 8: 210-11 (2008).

Publication Latest Publications

Title: HIV and hepatitis B co-infection in Africa
Authors: Lessells RJ, Main J, Cooke GS.
Journal: Lancet Infectious Diseases,8:210-11 (2008)

Journal Impact Factor (I.F.): 16.144
Number of citations (Google Scholar): 8


The Review by Christopher Hoff mann and Chloe Thio1 brings to the fore the issue of HIV and hepatitis B virus (HBV) co-infection in resource-poor settings. We support their call for further research in this fi eld. The management of HIV/HBV co-infection in highincome settings involves individualised therapy usually from an expert provider with the support of an array of diagnostic tests. The primary goal of this treatment is to reduce the risk of cirrhosis and hepatocellular carcinoma.

However, the public-health approach to antiretroviral therapy (ART) aims to maximise survival at the population level.2 ART programmes in Africa and other resource-poor settings involve standardised treatment protocols and simplifi ed monitoring to achieve best possible use of available resources. The treatment of hepatitis B is already entwined with the roll-out of ART since lamivudine, a key drug in most fi rst-line HIV treatment combinations, is also active against HBV.

Download: Full text paper

Citation: Lessells RJ, Main J, Cooke GS. HIV and hepatitis B co-infection in Africa Lancet Infectious Diseases,8:210-11 (2008).

Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration
Journal: EBioMedicine (2017)

High Rates of Transmission of Drug-resistant HIV in Aruba Resulting in Reduced Susceptibility to the WHO Recommended First-line Regimen in Nearly Half of Newly Diagnosed HIV-infected Patients
Journal: Clinical Infectious Diseases (2017)

Virological Outcomes of Second-line Protease Inhibitor-Based Treatment for Human Immunodeficiency Virus Type 1 in a High-Prevalence Rural South African Setting: A Competing-Risks Prospective Cohort Analysis
Journal: Clinical Infectious Diseases (2017)
All publications...

KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), K-RITH Tower Building, Nelson R Mandela School of Medicine, UKZN

Contact: Prof. Tulio de Oliveira, Tel: +27 31 260 4898, Email: &

Page design updated 2013. Many of the pages were previously hosted at